Total Payments
$181,522
2024 Payments
$19,185
Companies
33
Transactions
564
Medicare Patients
1,587
Medicare Billing
$288,615
Payment Breakdown by Category
Research$100,309 (55.3%)
Other$43,903 (24.2%)
Travel$20,458 (11.3%)
Food & Beverage$9,295 (5.1%)
Consulting$7,450 (4.1%)
Gifts$55.15 (0.0%)
Education$51.98 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $100,309 | 30 | 55.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $43,903 | 18 | 24.2% |
| Travel and Lodging | $20,458 | 66 | 11.3% |
| Food and Beverage | $9,295 | 442 | 5.1% |
| Consulting Fee | $7,450 | 3 | 4.1% |
| Gift | $55.15 | 3 | 0.0% |
| Education | $51.98 | 2 | 0.0% |
Payments by Type
Research
$100,309
30 transactions
General
$81,213
534 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $56,637 | 16 | $0 (2024) |
| JAZZ PHARMACEUTICALS INC. | $50,643 | 188 | $0 (2024) |
| PFIZER INC. | $41,921 | 9 | $0 (2023) |
| Merck Sharp & Dohme LLC | $20,488 | 80 | $0 (2022) |
| Harmony Biosciences LLC | $2,240 | 77 | $0 (2023) |
| Biogen, Inc. | $1,599 | 11 | $0 (2023) |
| Purdue Pharma L.P. | $1,447 | 6 | $0 (2017) |
| Genentech USA, Inc. | $1,393 | 5 | $0 (2023) |
| Amgen Inc. | $884.64 | 9 | $0 (2017) |
| Allergan Inc. | $732.59 | 3 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $19,185 | 5 | Eli Lilly and Company ($19,052) |
| 2023 | $73,968 | 57 | PFIZER INC. ($41,916) |
| 2022 | $10,090 | 54 | Eli Lilly and Company ($9,164) |
| 2021 | $842.45 | 58 | JAZZ PHARMACEUTICALS INC. ($336.50) |
| 2020 | $4,141 | 37 | Jazz Pharmaceuticals Inc. ($2,515) |
| 2019 | $6,596 | 67 | JAZZ PHARMACEUTICALS INC. ($4,599) |
| 2018 | $17,559 | 79 | Jazz Pharmaceuticals Inc. ($17,120) |
| 2017 | $49,141 | 207 | Jazz Pharmaceuticals Inc. ($25,351) |
All Payment Transactions
564 individual payment records from CMS Open Payments — Page 1 of 23
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/24/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $12,252.00 | Research |
| Study: A STUDY OF LY3556050 IN ADULT PARTICIPANTS WITH DIABETIC PERIPHERAL NEUROPATHIC PAIN | ||||||
| 09/24/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $3,800.00 | Research |
| Study: A STUDY OF RETATRUTIDE (LY3437943) IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT (TRIUMPH-1) | ||||||
| 09/24/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $3,000.00 | Research |
| Study: A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR OVERWEIGHT: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (TRIUMPH-1) | ||||||
| 04/09/2024 | IDORSIA PHARMACEUTICALS US INC | QUVIVIQ (Drug) | Food and Beverage | In-kind items and services | $20.41 | General |
| Category: Insomnia | ||||||
| 02/13/2024 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | Food and Beverage | In-kind items and services | $112.22 | General |
| Category: NEUROLOGY | ||||||
| 12/14/2023 | PFIZER INC. | NURTEC ODT (Drug) | — | Cash or cash equivalent | $2,160.30 | Research |
| Study: A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION WITH MULTIPLE DOSING REGIMENS • Category: PAIN | ||||||
| 11/17/2023 | Avadel CNS Pharmaceuticals, LLC | LUMRYZ (Drug) | Food and Beverage | In-kind items and services | $16.19 | General |
| Category: CENTRAL NERVOUS SYSTEM CNS NEUROLOGY | ||||||
| 11/16/2023 | IDORSIA PHARMACEUTICALS US INC | QUVIVIQ (Drug) | Food and Beverage | In-kind items and services | $22.24 | General |
| Category: INSOMNIA | ||||||
| 11/09/2023 | Harmony Biosciences LLC | WAKIX (Drug) | Food and Beverage | Cash or cash equivalent | $22.04 | General |
| Category: SLEEP MEDICINE | ||||||
| 10/19/2023 | JAZZ PHARMACEUTICALS INC. | RYLAZE (Drug) | Food and Beverage | In-kind items and services | $31.31 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 10/13/2023 | Biogen, Inc. | — | Travel and Lodging | In-kind items and services | $342.84 | General |
| 10/13/2023 | Biogen, Inc. | — | Travel and Lodging | Cash or cash equivalent | $75.41 | General |
| 10/13/2023 | Biogen, Inc. | — | Food and Beverage | In-kind items and services | $73.33 | General |
| 10/13/2023 | Biogen, Inc. | — | Food and Beverage | In-kind items and services | $62.55 | General |
| 10/13/2023 | Biogen, Inc. | — | Food and Beverage | In-kind items and services | $62.55 | General |
| 10/13/2023 | Biogen, Inc. | — | Food and Beverage | In-kind items and services | $50.40 | General |
| 10/13/2023 | Biogen, Inc. | — | Food and Beverage | Cash or cash equivalent | $40.94 | General |
| 10/12/2023 | PFIZER INC. | ZAVZPRET (Drug) | — | Cash or cash equivalent | $4,785.25 | Research |
| Study: A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION • Category: PAIN | ||||||
| 10/12/2023 | PFIZER INC. | NURTEC ODT (Drug) | — | Cash or cash equivalent | $1,104.85 | Research |
| Study: A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION WITH MULTIPLE DOSING REGIMENS • Category: PAIN | ||||||
| 10/12/2023 | Biogen, Inc. | — | Travel and Lodging | In-kind items and services | $488.10 | General |
| 10/12/2023 | Biogen, Inc. | — | Travel and Lodging | In-kind items and services | $246.24 | General |
| 10/12/2023 | Biogen, Inc. | — | Food and Beverage | In-kind items and services | $120.33 | General |
| 10/12/2023 | Biogen, Inc. | — | Travel and Lodging | Cash or cash equivalent | $35.91 | General |
| 10/11/2023 | Harmony Biosciences LLC | WAKIX (Drug) | Food and Beverage | Cash or cash equivalent | $28.35 | General |
| Category: SLEEP MEDICINE | ||||||
| 10/07/2023 | IDORSIA PHARMACEUTICALS US INC | QUVIVIQ (Drug) | Food and Beverage | In-kind items and services | $18.81 | General |
| Category: INSOMNIA | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A STUDY OF RETATRUTIDE (LY3437943) IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT (TRIUMPH-1) | Eli Lilly and Company | $27,075 | 2 |
| A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION WITH MULTIPLE DOSING REGIMENS | PFIZER INC. | $21,230 | 6 |
| A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION | PFIZER INC. | $20,686 | 2 |
| A STUDY OF LY3556050 IN ADULT PARTICIPANTS WITH DIABETIC PERIPHERAL NEUROPATHIC PAIN | Eli Lilly and Company | $12,787 | 2 |
| OBSTRUCTIVE SLEEP APNEA MASTER PROTOCOL GPIF: A STUDY OF TIRZEPATIDE (LY3298176) IN PARTICIPANTS WITH OBSTRUCTIVE SLEEP APNEA | Eli Lilly and Company | $6,125 | 2 |
| OBSTRUCTIVE SLEEP APNEA MASTER PROTOCOL GPIF: A STUDY OF TIRZEPATIDE (LY3298176) IN PARTICIPANTS WITH OBSTRUCTIVE SLEEP APNEA (SURMOUNT-OSA) | Eli Lilly and Company | $3,043 | 2 |
| A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR OVERWEIGHT: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (TRIUMPH-1) | Eli Lilly and Company | $3,000 | 1 |
| OBSTRUCTIVE SLEEP APNEA MASTER PROTOCOL GPIF A STUDY OF TIRZEPATIDE (LY3298176) IN PARTICIPANTS WITH OBSTRUCTIVE SLEEP APNEA | Eli Lilly and Company | $1,843 | 2 |
| A PHASE 4, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GALCANEZUMAB VERSUS RIMEGEPANT IN ADULT PARTICIPANTS WITH EPISODIC MIGRAINE | Eli Lilly and Company | $907.00 | 1 |
| A Study of the Efficacy and Safety of JZP-258 in Subjects With Narcolepsy With Cataplexy | Jazz Pharmaceuticals Inc. | $798.61 | 3 |
| A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR OVERWEIGHT: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL (TRIUMPH-1) | Eli Lilly and Company | $730.01 | 1 |
| A STUDY OF RETATRUTIDE (LY3437943) IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE OBESITY OR OVERWEIGHT (TRIUMPH-2) | Eli Lilly and Company | $730.01 | 1 |
| A MULTICENTER, RANDOMIZED, OPEN LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY AND TOLOERABILITY OF ORAL UBROGEPANT IN THE ACUTE TREATMENT OF MIGRANE WITH R WITHOUT AURA | Allergan Inc. | $356.00 | 1 |
| A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED SINGLE ATTACK STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF ORAL UBROGEPANT IN THE ACUTE TREATMENT OF MIGRAINE | Allergan Inc. | $356.00 | 1 |
| A Multicenter Study of the Efficacy and Safety of JZP-258 in the Treatment of Idiopathic Hypersomnia IH With an Open-label Safety Extension | Jazz Pharmaceuticals Inc. | $245.43 | 1 |
| RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN | Eli Lilly and Company | $232.00 | 1 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY2951742 IN PATIENTS WITH CHRONIC MIGRAINE - THE REGAIN STUDY | Eli Lilly and Company | $165.30 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 94 | 96 | $151,000 | $40,768 |
| 2022 | 4 | 147 | 153 | $182,840 | $49,534 |
| 2021 | 6 | 481 | 524 | $345,729 | $85,524 |
| 2020 | 6 | 865 | 1,020 | $507,765 | $112,788 |
Total Patients
1,587
Total Services
1,793
Medicare Billing
$288,615
Procedure Codes
19
All Medicare Procedures & Services
19 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 95811 | Sleep study in sleep lab with continuous airway pressure (6 years or older) | Office | 2023 | 40 | 41 | $77,900 | $20,888 | 26.8% |
| 95810 | Sleep study in sleep lab (6 years or older) | Office | 2023 | 38 | 38 | $64,600 | $18,711 | 29.0% |
| 95806 | Sleep study including heart rate, breathing, airflow, and effort | Office | 2023 | 16 | 17 | $8,500 | $1,169 | 13.7% |
| 95810 | Sleep study in sleep lab (6 years or older) | Office | 2022 | 54 | 54 | $91,800 | $27,191 | 29.6% |
| 95811 | Sleep study in sleep lab with continuous airway pressure (6 years or older) | Office | 2022 | 31 | 33 | $62,700 | $17,310 | 27.6% |
| 95806 | Sleep study including heart rate, breathing, airflow, and effort | Office | 2022 | 50 | 50 | $25,000 | $3,643 | 14.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 12 | 16 | $3,340 | $1,390 | 41.6% |
| 95811 | Sleep monitoring of patient (6 years or older) in sleep lab with continued pressured respiratory assistance by mask or breathing tube | Office | 2021 | 65 | 70 | $133,000 | $29,176 | 21.9% |
| 95810 | Sleep monitoring of patient (6 years or older) in sleep lab | Office | 2021 | 69 | 69 | $117,300 | $26,753 | 22.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 142 | 176 | $36,740 | $14,730 | 40.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 108 | 112 | $16,800 | $6,067 | 36.1% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 43 | 43 | $14,889 | $5,006 | 33.6% |
| 95806 | Unattended sleep study with recording of heart rate, oxygen, respiratory airflow and effort | Office | 2021 | 54 | 54 | $27,000 | $3,792 | 14.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 251 | 366 | $76,403 | $30,023 | 39.3% |
| 95810 | Sleep monitoring of patient (6 years or older) in sleep lab | Office | 2020 | 88 | 88 | $149,600 | $25,811 | 17.3% |
| 95811 | Sleep monitoring of patient (6 years or older) in sleep lab with continued pressured respiratory assistance by mask or breathing tube | Office | 2020 | 82 | 86 | $163,400 | $23,911 | 14.6% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 272 | 308 | $46,200 | $16,670 | 36.1% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 90 | 90 | $31,163 | $11,095 | 35.6% |
| 95806 | Unattended sleep study with recording of heart rate, oxygen, respiratory airflow and effort | Office | 2020 | 82 | 82 | $41,000 | $5,279 | 12.9% |
About Dr. John Hudson, M.D
Dr. John Hudson, M.D is a Sleep Medicine healthcare provider based in Austin, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/07/2006. The National Provider Identifier (NPI) number assigned to this provider is 1487626008.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Hudson, M.D has received a total of $181,522 in payments from pharmaceutical and medical device companies, with $19,185 received in 2024. These payments were reported across 564 transactions from 33 companies. The most common payment nature is "" ($100,309).
As a Medicare-enrolled provider, Hudson has provided services to 1,587 Medicare beneficiaries, totaling 1,793 services with total Medicare billing of $288,615. Data is available for 4 years (2020–2023), covering 19 distinct procedure/service records.
Ad
Practice Information
- Specialty Sleep Medicine
- Location Austin, TX
- Active Since 02/07/2006
- Last Updated 10/19/2018
- Taxonomy Code 2084S0012X
- Entity Type Individual
- NPI Number 1487626008
Products in Payments
- Xyrem (Drug) $39,632
- NURTEC ODT (Drug) $21,230
- ZAVZPRET (Drug) $20,686
- BELSOMRA (Drug) $19,673
- SUNOSI (Drug) $7,084
- Wakix (Drug) $2,047
- XYWAV (Drug) $700.57
- VYVANSE (Drug) $373.16
- Horizant (Drug) $366.96
- XYREM (Drug) $201.33
- WAKIX (Drug) $192.38
- RYLAZE (Drug) $185.80
- AJOVY (Drug) $173.51
- Briviact (Drug) $153.54
- MYDAYIS (Drug) $150.40
- Evekeo (Drug) $132.30
- Equetro (Drug) $132.03
- QUVIVIQ (Drug) $123.19
- Adzenys XR-ODT (Drug) $94.00
- Neupro (Drug) $83.69
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Sleep Medicine Doctors in Austin
Dr. Ashwin Gowda, M.d, M.D
Sleep Medicine — Payments: $28,338
Sleep Medicine $28,338
Ian Alward, Md, MD
Sleep Medicine — Payments: $17,904
Sleep Medicine $17,904
Dr. Vani Vallabhaneni, M.d, M.D
Sleep Medicine — Payments: $3,164
Sleep Medicine $3,164
Stanley Wang, M.d. J.d. M.p.h, M.D. J.D. M.P.H
Sleep Medicine — Payments: $1,590
Sleep Medicine $1,590
Joseph Leary, Md, MD
Sleep Medicine — Payments: $1,366
Sleep Medicine $1,366
June-Ku Kang, Md, MD
Sleep Medicine — Payments: $1,300
Sleep Medicine $1,300